Abstract: In the electrochromic device according to an embodiment of the present application, when the first voltage is applied to the electrochromic device in a state that the electrochromic element has the first state, the electrochromic device becomes the second state, and when the first voltage is applied to the electrochromic element in a state that the electrochromic element has the fourth state, the electrochromic element becomes the third state.

Abstract: In the electrochromic device according to an embodiment of the present application, when the first voltage is applied to the electrochromic device in a state that the electrochromic element has the first state, the electrochromic device becomes the second state, and when the first voltage is applied to the electrochromic element in a state that the electrochromic element has the fourth state, the electrochromic element becomes the third state.

Abstract: In the electrochromic device according to an embodiment of the present application, when the first voltage is applied to the electrochromic device in a state that the electrochromic element has the first state, the electrochromic device becomes the second state, and when the first voltage is applied to the electrochromic element in a state that the electrochromic element has the fourth state, the electrochromic element becomes the third state.

Abstract: The present application relates to an electrochromic device. In one aspect, the electrochromic device includes an electrochromic element including a first electrode, a second electrode, an electrochromic layer, an ion storage layer and the second electrode. The electrochromic device also includes controller configured to change a state of the electrochromic element to change to at least one of a first state having a first transmittance, a second state having a second transmittance, a third state having a third transmittance, or a fourth state having a fourth transmittance by applying power to the electrochromic element. When a first voltage is applied to the electrochromic element in a first state, the electrochromic element becomes the second state, and when the first voltage is applied to the electrochromic element in a fourth state, the electrochromic element becomes the third state.

Abstract: In the electrochromic device according to an embodiment of the present application, when the first voltage is applied to the electrochromic device in a state that the electrochromic element has the first state, the electrochromic device becomes the second state, and when the first voltage is applied to the electrochromic element in a state that the electrochromic element has the fourth state, the electrochromic element becomes the third state.

Abstract: The present application relates to an electrochromic device. In one aspect, the electrochromic device includes an electrochromic element including a first electrode, a second electrode, an electrochromic layer, an ion storage layer and the second electrode. The electrochromic device also includes controller configured to change a state of the electrochromic element to change to at least one of a first state having a first transmittance, a second state having a second transmittance, a third state having a third transmittance, or a fourth state having a fourth transmittance by applying power to the electrochromic element. When a first voltage is applied to the electrochromic element in a first state, the electrochromic element becomes the second state, and when the first voltage is applied to the electrochromic element in a fourth state, the electrochromic element becomes the third state.

Abstract: Provided is a pharmaceutical composition for the treatment and/or prevention of disease involving metabolic syndromes, comprising (a) a therapeutically effective amount of a particular compound represented by Formula 1 as defined in the specification, or isomer, prodrug, or solvate or thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

Abstract: Provided is a pharmaceutical composition for the treatment and/or prevention of disease involving metabolic syndromes, comprising (a) a therapeutically effective amount of a particular compound represented by Formula 1 as defined in the specification, or isomer, prodrug, or solvate or thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

Abstract: Provided is a use of a prodrug composition containing a naphthoquinone-based compound of Formula 1 for the manufacture of a medicament for treatment or prevention of metabolic syndrome diseases. wherein R1 to R10, X, m and n are as defined in the specification.